dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gazzah, A. |
dc.contributor.author | Bedard, Philippe L. |
dc.contributor.author | Hierro Carbó, Cinta |
dc.contributor.author | Kang, Yoon-Koo |
dc.contributor.author | Abdul Razak, A. |
dc.contributor.author | Ryu, M.-H. |
dc.contributor.author | Tabernero Caturla, Josep |
dc.date.accessioned | 2022-09-06T09:14:51Z |
dc.date.available | 2022-09-06T09:14:51Z |
dc.date.issued | 2022-04 |
dc.identifier.citation | Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416–25. |
dc.identifier.issn | 0923-7534 |
dc.identifier.uri | https://hdl.handle.net/11351/8032 |
dc.description | Conjugado anticuerpo-fármaco; Estudio de escalada de dosis; Tusamitamab ravtansina |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Annals of Oncology;33(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Farmacocinètica |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Dose-Response Relationship, Drug |
dc.subject.mesh | Treatment Outcome |
dc.title | Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.annonc.2021.12.012 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | relación dosis-respuesta de medicamentos |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1016/j.annonc.2021.12.012 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Gazzah A] Drug Development Department, Gustave Roussy, Villejuif Cedex, Villejuif, France. [Bedard PL, Abdul Razak A] Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre–University Health Network, University of Toronto, Toronto, Canada. [Hierro C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Kang YK, Ryu MH] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medical Oncology Department, IOB-Quiron, UVic-UCC, Barcelona, Spain |
dc.identifier.pmid | 35026412 |
dc.identifier.wos | 000820214100008 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |